PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17634479-0	2007	Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.	Tamoxifen	97-106	epidermal growth factor receptor	Homo sapiens	28-60	
17634479-2	2007	Here we assess the relationship between EGFR expression and tamoxifen response, with a new quantitative technology.	Tamoxifen	60-69	epidermal growth factor receptor	Homo sapiens	40-44	
17634479-5	2007	RESULTS: In ER-positive patients, tamoxifen-treated patients with low EGFR expression (n = 113) showed a significant effect by 2 years of adjuvant tamoxifen (P = .01), in contrast to no treatment effect in the EGFR-high group (n = 73, P = .69).	Tamoxifen	34-43	epidermal growth factor receptor	Homo sapiens	70-74	
17634479-5	2007	RESULTS: In ER-positive patients, tamoxifen-treated patients with low EGFR expression (n = 113) showed a significant effect by 2 years of adjuvant tamoxifen (P = .01), in contrast to no treatment effect in the EGFR-high group (n = 73, P = .69).	Tamoxifen	34-43	epidermal growth factor receptor	Homo sapiens	210-214	
17634479-5	2007	RESULTS: In ER-positive patients, tamoxifen-treated patients with low EGFR expression (n = 113) showed a significant effect by 2 years of adjuvant tamoxifen (P = .01), in contrast to no treatment effect in the EGFR-high group (n = 73, P = .69).	Tamoxifen	147-156	epidermal growth factor receptor	Homo sapiens	70-74	
17634479-7	2007	A significant beneficial effect of tamoxifen treatment was seen in the EGFR-low group (hazard ratio [HR] = 0.43 (95% CI, 0.22 to 0.84; P = .013) in contrast to no effect in the EGFR-high group (HR = 1.14; 95% CI, 0.59 to 2.22; P = .7) by using a Cox model.	Tamoxifen	35-44	epidermal growth factor receptor	Homo sapiens	71-75	
17634479-7	2007	A significant beneficial effect of tamoxifen treatment was seen in the EGFR-low group (hazard ratio [HR] = 0.43 (95% CI, 0.22 to 0.84; P = .013) in contrast to no effect in the EGFR-high group (HR = 1.14; 95% CI, 0.59 to 2.22; P = .7) by using a Cox model.	Tamoxifen	35-44	epidermal growth factor receptor	Homo sapiens	177-181	
17634479-8	2007	CONCLUSION: This study provides clinical evidence that confirms the basic work that has shown high EGFR can indicate resistance to tamoxifen.	Tamoxifen	131-140	epidermal growth factor receptor	Homo sapiens	99-103